Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

16.75 +0.06 (+0.39%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets ↗

April 10, 2025

Via The Motley Fool

Topics ETFs

PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday ↗

April 10, 2025

Via Benzinga

2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a Decade ↗

April 06, 2025

Via The Motley Fool

Topics Government

3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months ↗

April 03, 2025

Via The Motley Fool

Topics Artificial Intelligence Economy World Trade

Is Summit Therapeutics a Millionaire Maker? ↗

February 09, 2025

Via The Motley Fool

2 Stocks That Could Soar Again in 2025 ↗

February 08, 2025

Via The Motley Fool

Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today ↗

March 31, 2025

Via The Motley Fool

Topics Government World Trade

Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades. ↗

March 31, 2025

Via The Motley Fool

Topics Intellectual Property Retirement

Why Summit Therapeutics Stock Slipped Today ↗

March 26, 2025

Via The Motley Fool

Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics ↗

March 24, 2025

Summit Therapeutics' ivonescimab shows strong efficacy in trials, with Cantor Fitzgerald predicting a 50% market share in the $100B VEGF x PD-(L)1 space.

Via Benzinga

Is Summit Therapeutics a Millionaire Maker? ↗

March 23, 2025

Via The Motley Fool

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 21, 2025

From Summit Therapeutics Inc.

Via Business Wire

This Unstoppable Biotech Stock Just Became an Even Better Buy ↗

March 19, 2025

Via The Motley Fool

Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

March 17, 2025

From Summit Therapeutics Inc.

Via Business Wire

Applovin, Super Micro Computer And Intel Among Top 10 Large-Cap Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? ↗

March 16, 2025

Top 10 large-cap stocks rose last week: Rubrik 23.17%, Applovin 17.21%, Summit Therapeutics 16.93%, Intel 16.52%, VG 16.03%, GE Vernova 14.01%, Samsara 11.96%, Antero Resources 11.68%, Super Micro...

Via Benzinga

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 14, 2025

From Summit Therapeutics Inc.

Via Business Wire

Why Summit Therapeutics Stock Was Winning This Week ↗

March 14, 2025

Via The Motley Fool

This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year ↗

March 13, 2025

Via The Motley Fool

2025 March Market Cap Showdown: Andy Cross vs. Matt Argersinger ↗

March 10, 2025

Via The Motley Fool

This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

February 28, 2025

Via Benzinga

Summit Therapeutics’ Retail Chatter Explodes As Pfizer Trial Pact Drowns Out Q4 Letdown ↗

February 24, 2025

Message volume on Stocktwits jumped 2,500%, with retail traders focusing on Summit’s partnership to evaluate ivonescimab in combination with Pfizer’s antibody-drug conjugates for solid tumors.

Via Stocktwits

Palantir Extends Losses, Microsoft Slides: What's Driving Markets Monday? ↗

February 24, 2025

The major indices struggled to maintain early momentum on Monday, but appear to climbing back with the S&P 500 and Dow Jones both green in midday trading.

Via Benzinga

Topics Stocks

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024

February 24, 2025

From Summit Therapeutics Inc.

Via Business Wire

Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)

February 24, 2025

From Summit Therapeutics Inc.

Via Business Wire

Earnings Scheduled For February 24, 2025 ↗

February 24, 2025

Via Benzinga

Consumer Sentiment Drops 10%, UnitedHealth Under Investigation: What's Driving Markets Friday? ↗

February 21, 2025

All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about the economic outlook.

Via Benzinga

Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025

February 18, 2025

From Summit Therapeutics Inc.

Via Business Wire

3 Stocks That Could Trounce the Market in 2025 ↗

February 17, 2025

Via The Motley Fool

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 14, 2025

From Summit Therapeutics Inc.

Via Business Wire

Jim Cramer Says AppFolio Is A 'Good One,' But Summit Therapeutics? 'Can't Go There' ↗

February 03, 2025

On CNBC's "Mad Money Lightning Round," Jim Cramer said Summit Therapeutics is "obviously just a very big spec."

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.